Pharma Mar Overview
- Year Founded
-
1986
- Status
-
Public
- Employees
-
382
- Stock Symbol
-
PHM
- Investments
-
1
- Share Price
-
$84.72
- (As of Monday Closing)
Pharma Mar General Information
Description
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
Contact Information
Website
www.pharmamar.comCorporate Office
- Avenida De los Reyes, 1
- 28770 Colmenar Viejo
- Spain
Corporate Office
- Avenida De los Reyes, 1
- 28770 Colmenar Viejo
- Spain
Pharma Mar Stock Performance
As of 12-May-2025, Pharma Mar’s stock price is $84.72. Its current market cap is $1.46B with 17.3M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $84.72 | $82.98 | $34.07 - $110.17 | $1.46B | 17.3M | 62.5K | $1.21 |
Pharma Mar Financials Summary
As of 31-Mar-2025, Pharma Mar has a trailing 12-month revenue of $189M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,413,023 | 1,324,106 | 663,621 | 1,098,508 |
| Revenue | 188,665 | 189,210 | 171,133 | 206,436 |
| EBITDA | 18,484 | 16,840 | 483 | 53,822 |
| Net Income | 21,337 | 28,270 | 1,230 | 51,893 |
| Total Assets | 360,954 | 363,830 | 376,411 | 421,730 |
| Total Debt | 56,216 | 53,147 | 48,272 | 45,716 |
Pharma Mar Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pharma Mar Comparisons
Industry
Financing
Details
Pharma Mar Competitors (3)
One of Pharma Mar’s 3 competitors is Lupin, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lupin | Corporation | Mumbai, India | ||||
| Cipla | Corporation | Mumbai, India | ||||
| GlaxoSmithKline Consumer Nigeria | Corporation | Lagos, Nigeria |
Pharma Mar Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pharma Mar Patents
Pharma Mar Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022381992-A1 | Lurbinectedin and atezolizumab combinations | Pending | 08-Nov-2021 | ||
| CA-3237009-A1 | Lurbinectedin and atezolizumab combinations | Pending | 08-Nov-2021 | ||
| EP-4430075-A1 | Lurbinectedin and atezolizumab combinations | Pending | 08-Nov-2021 | ||
| JP-2024540417-A | Combination of lurbinectedin and atezolizumab | Pending | 08-Nov-2021 | ||
| US-20240415834-A1 | Lurbinectedin and atezolizumab combinations | Pending | 08-Nov-2021 | A61K31/4995 |
Pharma Mar Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pharma Mar Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pharma Mar Acquisitions (1)
Pharma Mar’s most recent deal was a Merger/Acquisition with Zeltia. The deal was made on 02-Nov-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zeltia | 02-Nov-2014 | Merger/Acquisition | Biotechnology |
Pharma Mar ESG
Risk Overview
Risk Rating
Updated March, 28, 2025
27.5 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Biotechnology
Subindustry
of 365
Rank
Percentile
Pharma Mar Exits (1)
Pharma Mar’s most recent exit was on 02-Nov-2014 from Zeltia. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Zeltia | 02-Nov-2014 | Completed |
|
Pharma Mar FAQs
-
When was Pharma Mar founded?
Pharma Mar was founded in 1986.
-
Where is Pharma Mar headquartered?
Pharma Mar is headquartered in Colmenar Viejo, Spain.
-
What is the size of Pharma Mar?
Pharma Mar has 382 total employees.
-
What industry is Pharma Mar in?
Pharma Mar’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Pharma Mar a private or public company?
Pharma Mar is a Public company.
-
What is Pharma Mar’s stock symbol?
The ticker symbol for Pharma Mar is PHM.
-
What is the current stock price of Pharma Mar?
As of 12-May-2025 the stock price of Pharma Mar is $84.72.
-
What is the current market cap of Pharma Mar?
The current market capitalization of Pharma Mar is $1.46B.
-
What is Pharma Mar’s current revenue?
The trailing twelve month revenue for Pharma Mar is $189M.
-
Who are Pharma Mar’s competitors?
Lupin, Cipla, and GlaxoSmithKline Consumer Nigeria are competitors of Pharma Mar.
-
What is Pharma Mar’s annual earnings per share (EPS)?
Pharma Mar’s EPS for 12 months was $1.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
